Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gnmlf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) measures how much investors pay for each dollar of the company's trailing earnings. GNMLF's current PE ratio of 8.70x is calculated by dividing its stock price of $0.95 by its TTM earnings per share of $1.71. −37.4% discount vs 5Y avg 13.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 18 fiscal years · Front-end computedMinQ1 · 25%18.6x
MedianQ3 · 75%124.2x
Max
At 8.70x, GNMLF's current P/E is lower than in 0% of its annual fiscal year readings over the past 18 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Genomma Lab Internacional, S.A.B. de C.V.You GNMLF | $929M | 8.70x | -54.8% | $1.71 |
 BioGaia AB (publ) BIOGY | $1.1B | 30.83x | +60.2% | $3.29 |
 Extendicare Inc. EXETF | $2.1B | 18.86x | -2.0% | $1.13 |
 Kissei Pharmaceutical Co., Ltd. KSPHF | $1.3B | 12.26x | -36.3% | $333.61 |
 SSY Group Limited LJUIF | $1.2B | 19.53x | +1.5% | $0.16 |
 Netcare Limited NWKHY | $844M | 8.68x | -54.9% | $14.24 |
 Rhoen-Klinikum AG RHKJF | $1.0B | 25.30x | +31.5% | $0.51 |
Industry Average 6 peers with valid PE | — | 19.24x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 11.58x | $1.65 | -33.3% | |
2024-12-31 FY2024 | 17.37x | $1.53 | +40.9% | |
2023-12-31 FY2023 | 12.33x | $1.16 | +6.4% | |
2022-12-31 FY2022 | 11.59x | $1.41 | -30.2% | |
2021-12-31 FY2021 | 16.60x | $1.30 | +20.8% | |
2020-12-31 FY2020 | 13.75x | $1.39 | -42.3% | |
2019-12-31 FY2019 | 23.84x | $0.77 | +156.5% | |
2018-12-31 FY2018 | 9.30x | $1.09 | -34.9% | |
2017-12-31 FY2017 | 14.29x | $1.36 | — | |
2016-12-31 FY2016 | — | $-1.72 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) measures how much investors pay for each dollar of the company's trailing earnings. GNMLF's current PE ratio of 8.70x is calculated by dividing its stock price of $0.95 by its TTM earnings per share of $1.71.
Frequently asked questions
GNMLF pe ratio · 6 questionsGNMLF's current PE ratio is 8.70x as of 2026-06-08, based on a stock price of $0.95 and TTM EPS of $1.71. Data sourced from Financial Modeling Prep via GNMLF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Genomma Lab Internacional, S.A.B. de C.V. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08